Integration of artificial intelligence and high-content screening enabled identification of drugs for long-term treatment of cerebral cavernous malformation disease

Predictions using AI technology and high-throughput drug screening, combined with pharmacokinetic, pharmacodynamic, and toxicological studies in CCM animal models, identified metformin as a promising drug candidate for repurposing for the long-term treatment of CCM disease. We propose that metformin enhances metabolic adaptation to brain vascular malformations by activating AMPK, which helps reverse mitochondrial fragmentation in brain endothelial cells.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2025-12-11
DOI
https://doi.org/10.64898/2025.12.08.693036
Primary Topic
Vascular Malformations Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integration of artificial intelligence and high-content screening enabled identification of drugs for long-term treatment of cerebral cavernous malformation disease

Bethan S. Kilpatrick, Hemal H. Patel, Ingrid R. Niesman, Janeth O. Birrueta et al.
bioRxiv (Cold Spring Harbor Laboratory)
Vascular Malformations Diagnosis and Treatment
article

Integration of artificial intelligence and high-content screening enabled identification of drugs for long-term treatment of cerebral cavernous malformation disease

Bethan S. Kilpatrick, Hemal H. Patel, Ingrid R. Niesman, Janeth O. Birrueta, Helios Gallego-Gutiérrez, Brina Nguyen, Jeffrey Steinberg, Jeremiah D. Momper, Andrea Taddei, Anil Sawhney, JoAnn Trejo, Brendan Gongol, Eduardo Frías-Anaya, Issam A. Awad, Miguel Alejandro Lopez‐Ramirez, Cassandra Bui, Zaida Mizushima
article en

Abstract

Predictions using AI technology and high-throughput drug screening, combined with pharmacokinetic, pharmacodynamic, and toxicological studies in CCM animal models, identified metformin as a promising drug candidate for repurposing for the long-term treatment of CCM disease. We propose that metformin enhances metabolic adaptation to brain vascular malformations by activating AMPK, which helps reverse mitochondrial fragmentation in brain endothelial cells.

bioRxiv (Cold Spring Harbor Laboratory)
University of California, Riverside (US), San Diego State University (US), University of California San Diego (US), VA San Diego Healthcare System (US), BenevolentAI (United Kingdom) (GB), Neurological Surgery (US), University of Montana (US)
Openalex Percentile: Top 46%
Vascular Malformations Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.